Illumina (NASDAQ:ILMN – Get Free Report) issued its quarterly earnings results on Thursday. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08, FiscalAI reports. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company earned $1.19 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina updated its FY 2026 guidance to 5.300-5.400 EPS.
Here are the key takeaways from Illumina’s conference call:
- Q2 exceeded expectations: Revenue rose 9.5% year over year to $1.16 billion, organic rest-of-world growth was 8.1%, and non-GAAP EPS increased 10% to $1.31. Operating margin also came in above guidance despite higher freight and memory costs.
- Clinical demand remains the primary growth engine, with clinical sequencing consumables up 15% outside China and U.S.-Canada growth above 20%. Illumina placed more than 95 NovaSeq X instruments in the quarter, expanding the installed base and supporting future consumables pull-through.
- Management raised full-year 2026 guidance to rest-of-world organic revenue growth above 5%, reported revenue of $4.60 billion-$4.64 billion, and non-GAAP EPS of $5.30-$5.40. The company continues to target high-single-digit revenue growth in 2027.
- Research and academic customers remain cautious amid funding uncertainty; research and applied consumables declined 7% in the quarter, and Illumina still expects mid- to high-single-digit declines in this market for 2026.
- Illumina is expanding beyond core sequencing through spatial biology, proteomics, and BioInsite. The Billion Cell Atlas has delivered more than 300 million cells, generated initial revenue, and added three partners after quarter-end, bringing the total to six, although management characterized the opportunity as still early.
Illumina Stock Performance
NASDAQ ILMN traded up $10.27 on Thursday, reaching $205.09. 2,763,533 shares of the company’s stock traded hands, compared to its average volume of 1,646,504. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $205.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 37.29, a P/E/G ratio of 2.88 and a beta of 1.47. The stock has a 50 day moving average price of $175.49 and a 200-day moving average price of $146.83.
Insider Buying and Selling at Illumina
Institutional Investors Weigh In On Illumina
Hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Illumina during the third quarter valued at $32,000. Brown Brothers Harriman & Co. raised its position in shares of Illumina by 975.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock worth $58,000 after acquiring an additional 400 shares during the period. Itau Unibanco Holding S.A. boosted its stake in shares of Illumina by 93.1% during the 4th quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock worth $73,000 after acquiring an additional 268 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Illumina during the 3rd quarter worth about $102,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Illumina by 16.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,329 shares of the life sciences company’s stock valued at $176,000 after acquiring an additional 186 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the stock. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Piper Sandler lifted their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $156.88.
Read Our Latest Research Report on ILMN
Key Stories Impacting Illumina
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Q2 beat expectations: Revenue rose approximately 9.4% year over year to $1.16 billion, exceeding the $1.13 billion consensus estimate. Non-GAAP diluted EPS was $1.31, above expectations of about $1.23, while GAAP diluted EPS reached $1.35. Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised
- Positive Sentiment: Improved operating performance: Gross profit increased 10.8% to $770 million, and operating profit rose 14.5% to $245 million. Illumina reported a 21.1% GAAP operating margin and a 22.5% non-GAAP operating margin, supporting the case for expanding profitability. Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
- Positive Sentiment: FY 2026 outlook was favorable: Adjusted EPS guidance was set at $5.30-$5.40, above the roughly $5.23 analyst consensus. Revenue guidance of approximately $4.6 billion, with a midpoint near $4.62 billion, was also modestly ahead of expectations. Illumina Surprises With Q2 Sales and Outlook
- Positive Sentiment: Strategic validation: Eli Lilly joined Illumina’s Billion Cell Atlas alliance as a foundational participant, potentially strengthening Illumina’s position in genomic data and AI-driven drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
- Neutral Sentiment: Reported insider trading data showed substantially more selling than buying over the past six months, although the activity was not directly tied to the quarterly announcement and may have limited near-term relevance.
Illumina Company Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
